.png){kind=icon}
.png){kind=icon}
Return
Bladder Cancer, Version 5.2017
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2017.0156.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Keywords:
TRANSITIONAL-CELL CARCINOMA
PHASE-III TRIAL
GEMCITABINE PLUS CISPLATIN
LONG-TERM OUTCOMES
METASTATIC UROTHELIAL CARCINOMA
DOSE-DENSE METHOTREXATE
NEOADJUVANT CHEMOTHERAPY
ADJUVANT CHEMOTHERAPY
RADICAL CYSTECTOMY
URINARY-BLADDER
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations